Literature DB >> 7590770

Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53.

I F Ciernik1, J Berzofsky, D P Carbone.   

Abstract

The p53 nuclear oncoprotein frequently contains somatically acquired missense mutations and is often overexpressed in cancer cells. It is now known that nuclear and cytosolic proteins are processed into peptides and these can be transported into the endoplasmic reticulum and presented on the cell surface with class I MHC. We have previously shown that after treatment with interferon gamma (IFN-gamma), BALB/c 3T3 fibroblasts transfected with mutant p53 (135 C to Y) can be specifically lysed by mutant peptide-induced CTL. Here we show that P815 mastocytomas are effectively lysed by peptide stimulated CTL without treatment of IFN-gamma in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590770     DOI: 10.1089/hyb.1995.14.139

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  4 in total

Review 1.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

Review 2.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

3.  Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses.

Authors:  T Ishida; S Chada; M Stipanov; S Nadaf; F I Ciernik; D I Gabrilovich; D P Carbone
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

4.  Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Authors:  Adam Vigil; Osvaldo Martinez; Mark A Chua; Adolfo García-Sastre
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.